Mimicking the Osteosarcoma Bone Microenvironment Using MEW‐Printed PCL Scaffolds
Source abstract
Abstract
ABSTRACT Osteosarcoma is the most common primary malignant bone tumor, typically affecting children and adolescents during rapid growth periods. With current treatments, the five‐year survival rate for metastatic or recurrent cases remains only 20–30%, highlighting the need for new therapeutic approaches and better preclinical models. Our goal is to simulate the osteosarcoma bone microenvironment using melt electrowriting (MEW)‐printed polycaprolactone (PCL) scaffolds with optimized calcium phosphate formation. To achieve this, we fabricated PCL scaffolds with distinct MEW micro‐architectures, including rectangular, triangular, and hexagonal designs with comparable primary fiber spacing, and investigated two calcium phosphate formation methods: natural cell‐generated mineralization and direct calcium phosphate cement coating. Using SaOS‐2 osteosarcoma cells, we systematically evaluated cell behavior, mineralization dynamics, and scaffold mechanical properties. This approach aims to establish a biomimetic 3D model that bridges the gap between laboratory findings and clinical applications, enabling more pathophysiologically relevant drug testing platforms.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Electrospun Nanofibers in Biomedical Applications · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
University Center of Orthopaedic Trauma and Plastic Surgery University Hospital Carl Gustav Carus and Faculty of Medicine at TUD Dresden University of Technology Dresden Germany
Center for Translational Bone Joint and Soft Tissue Research University Hospital Carl Gustav Carus and Faculty of Medicine at TUD Dresden University of Technology Dresden Germany
References (66)
Show source-provided references
1. 10.3322/caac.2182010.3322/caac.21820 ↗
2. 10.3390/jcm1208278510.3390/jcm12082785 ↗
3. 10.1080/14737140.2018.141393910.1080/14737140.2018.1413939 ↗
4. 10.1016/j.cellimm.2017.10.01110.1016/j.cellimm.2017.10.011 ↗
5. 10.1016/S0304‐3835(24)00053‐310.1016/S0304‐3835(24)00053‐3 ↗
6. 10.1016/j.jbo.2025.10069810.1016/j.jbo.2025.100698 ↗
7. 10.1016/j.coph.2014.02.00210.1016/j.coph.2014.02.002 ↗
8. 10.1002/ijc.2937610.1002/ijc.29376 ↗
9. 10.1093/rb/rbaf08710.1093/rb/rbaf087 ↗
10. 10.1007/s10555‐025‐10257‐310.1007/s10555‐025‐10257‐3 ↗
11. StatPearls, Ifosfamide Use in Pediatric Osteosarcoma Patients
12. 10.1038/ncomms451110.1038/ncomms4511 ↗
13. 10.1021/acsptsci.5c0053010.1021/acsptsci.5c00530 ↗
14. 10.1007/s11864‐009‐0087‐310.1007/s11864‐009‐0087‐3 ↗
15. 10.1038/s41598‐024‐53802‐w10.1038/s41598‐024‐53802‐w ↗
16. 10.3389/fmolb.2024.132745910.3389/fmolb.2024.1327459 ↗
17. 10.1016/j.biomaterials.2013.11.05010.1016/j.biomaterials.2013.11.050 ↗
18. 10.1111/j.1582‐4934.2009.00853.x10.1111/j.1582‐4934.2009.00853.x ↗
19. 10.1016/j.jbiotec.2010.01.01210.1016/j.jbiotec.2010.01.012 ↗
20. 10.1002/adma.20110348210.1002/adma.201103482 ↗
21. 10.1038/s41598‐018‐19502‐y10.1038/s41598‐018‐19502‐y ↗
22. 10.1002/adem.20230126010.1002/adem.202301260 ↗
23. 10.1088/1748‐605X/ac730810.1088/1748‐605X/ac7308 ↗
24. 10.18063/ijb.v8i3.55610.18063/ijb.v8i3.556 ↗
25. 10.1038/s42003‐022‐04320‐w10.1038/s42003‐022‐04320‐w ↗
26. 10.1016/j.tibtech.2024.03.00810.1016/j.tibtech.2024.03.008 ↗
27. 10.1039/C2BM00039C10.1039/C2BM00039C ↗
28. 10.1002/adtp.20230021810.1002/adtp.202300218 ↗
29. 10.3390/polym1516343110.3390/polym15163431 ↗
30. 10.1002/pc.2934510.1002/pc.29345 ↗
31. 10.1016/J.PROGPOLYMSCI.2019.05.00410.1016/J.PROGPOLYMSCI.2019.05.004 ↗
32. 10.1016/j.toxrep.2024.10186310.1016/j.toxrep.2024.101863 ↗
33. 10.1016/j.drudis.2013.12.00610.1016/j.drudis.2013.12.006 ↗
34. 10.1016/j.matdes.2023.11161810.1016/j.matdes.2023.111618 ↗
35. 10.1002/adfm.20250935710.1002/adfm.202509357 ↗
36. 10.1016/j.matdes.2024.11285310.1016/j.matdes.2024.112853 ↗
37. 10.1002/jcp.2607610.1002/jcp.26076 ↗
38. 10.1002/jcb.2248510.1002/jcb.22485 ↗
39. 10.1038/s41571‐021‐00519‐810.1038/s41571‐021‐00519‐8 ↗
40. 10.1186/s12938‐021‐00860‐010.1186/s12938‐021‐00860‐0 ↗
41. 10.1200/jco.2002.20.3.77610.1200/jco.2002.20.3.776 ↗
42. 10.1016/j.mtchem.2024.10225310.1016/j.mtchem.2024.102253 ↗
43. 10.3390/life1311214110.3390/life13112141 ↗
44. 10.1088/1758‐5090/abe5b410.1088/1758‐5090/abe5b4 ↗
45. 10.1016/j.msec.2019.11018610.1016/j.msec.2019.110186 ↗
46. 10.1016/j.msec.2021.11209110.1016/j.msec.2021.112091 ↗
47. 10.1093/rb/rbac00510.1093/rb/rbac005 ↗
48. 10.1016/j.msec.2016.08.01910.1016/j.msec.2016.08.019 ↗
49. 10.1016/j.msec.2020.11147010.1016/j.msec.2020.111470 ↗
50. 10.1089/ten.TEA.2020.012110.1089/ten.TEA.2020.0121 ↗
51. 10.1002/adfm.20180315110.1002/adfm.201803151 ↗
52. 10.1242/dev.09406010.1242/dev.094060 ↗
53. 10.1002/jbm.a.3628810.1002/jbm.a.36288 ↗
54. 10.1016/j.msec.2015.05.01110.1016/j.msec.2015.05.011 ↗
55. 10.3389/fbioe.2023.112716210.3389/fbioe.2023.1127162 ↗
56. 10.1016/j.mechmat.2020.10372710.1016/j.mechmat.2020.103727 ↗
57. 10.1016/j.actbio.2020.07.01010.1016/j.actbio.2020.07.010 ↗
58. 10.1002/adem.20220174310.1002/adem.202201743 ↗
59. 10.1089/ten.tea.2020.012110.1089/ten.tea.2020.0121 ↗
60. 10.1021/acs.langmuir.2c0103810.1021/acs.langmuir.2c01038 ↗
61. 10.1007/s10237‐019‐01188‐410.1007/s10237‐019‐01188‐4 ↗
62. 10.1002/jbm.b.3446710.1002/jbm.b.34467 ↗
63. 10.1002/adhm.20240095710.1002/adhm.202400957 ↗
64. 10.3389/fbioe.2024.144498610.3389/fbioe.2024.1444986 ↗
65. 10.1002/adhm.20230041110.1002/adhm.202300411 ↗
66. 10.3390/md2207029510.3390/md22070295 ↗